Study identifies barriers to GLP-1 agonist use for obesity management among patients, including cost, insurance denial, side effects, and prescriber hesitancy.
Key findingStudy identifies barriers to GLP-1 agonist use for obesity management among patients, including cost
What the researchers found
Study identifies barriers to GLP-1 agonist use for obesity management among patients, including cost, insurance denial, side effects, and prescriber hesitancy.
Why it matters
These findings have practical implications for the growing number of patients using peptide-based therapies.
The numbers in context
Cross-sectional study conducted January–October 2024 in Tabuk, Saudi Arabia surveying the general population.
How the study worked
Study methodology detailed in the full publication.
Who was studied
General population in Tabuk City, Saudi Arabia
What this study cannot tell us
Study limitations in the full publication.
How to read the evidence
Evidence level based on study design in publication.
When this study was published
Published in 2025.
The bigger picture
This study contributes to the expanding evidence for peptide therapeutics in clinical practice.
Questions still open
- What are the long-term implications?
- How do results compare to other evidence?
- What further research is needed?
Common questions
What does this mean for patients?
How reliable is this?
Read the original research
Barriers to glucagon-like peptide-1 agonists used for obesity management among the general population in Tabuk City, Saudi Arabia, and their relation to smoking cessation and antidepressants.
Frontiers in pharmacology, 16, 1510554
Citation
Alhowiti, Amirah; Mirghani, Hyder; Abdulrahman Qrmli, Abdulaziz; Albalawi, Amal Abdullah; Abdulrahman Aljohani, Raneem. (2025). Barriers to glucagon-like peptide-1 agonists used for obesity management among the general population in Tabuk City, Saudi Arabia, and their relation to smoking cessation and antidepressants.. Frontiers in pharmacology, 16, 1510554. https://doi.org/10.3389/fphar.2025.1510554